—
C+
C+ The full Closelook — membership. Open the C+ overview

Krystal Biotech Inc (KRYS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Krystal Biotech Inc

KRYS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines for diseases with few existing treatments. Its approved product, VYJUVEK, treats a rare skin disorder called dystrophic epidermolysis bullosa. The company also runs a pipeline of experimental gene-based therapies for conditions such as cystic fibrosis, ocular disease and certain skin conditions. Founded in 2016, it is headquartered in Pittsburgh, Pennsylvania.
Where it sits in the stack
Krystal Biotech holds no seat in Rubin or Halo, our indices for the AI build-out; it sits outside that stack entirely, in the healthcare and biotechnology sleeve of the wider universe the diary follows, as a maker of gene-based therapies rather than a supplier to compute infrastructure.
Who it is priced against
Closelook's peer group holds no comparison set for Krystal Biotech; the diary notes the market sometimes compares it with Ultragenyx Pharmaceutical, another gene-therapy focused biotech.
Why Closelook tracks it
Krystal Biotech holds no seat in Rubin or Halo and has not appeared in any of our editions to date. It carries a Closelook score, but with only one module scored so far, the score is still being built.
What the diary watches
The diary watches how sales of VYJUVEK develop and whether pipeline programmes such as those for cystic fibrosis and ocular disease progress through further trials.

Krystal Biotech Inc (KRYS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for KRYS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Krystal Biotech Inc (KRYS)?

Krystal Biotech Inc trades as KRYS on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is KRYS in a Closelook index?

Not currently — Krystal Biotech Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does KRYS trade against its moving averages?

Pullback inside an uptrend stack: Trades -1.8% vs the 50-day and +14.6% vs the 200-day average, 11.4% below the 52-week high and +121.1% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Krystal Biotech Inc do?

Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines for diseases with few existing treatments. Its approved product, VYJUVEK, treats a rare skin disorder called dystrophic epidermolysis bullosa. The company also runs a pipeline of experimental gene-based therapies for conditions such as cystic fibrosis, ocular disease and certain skin conditions. Closelook's peer group holds no comparison set for Krystal Biotech; the diary notes the market sometimes compares it with Ultragenyx Pharmaceutical, another gene-therapy focused biotech.

Where does Krystal Biotech Inc sit in the AI build-out?

Krystal Biotech holds no seat in Rubin or Halo, our indices for the AI build-out; it sits outside that stack entirely, in the healthcare and biotechnology sleeve of the wider universe the diary follows, as a maker of gene-based therapies rather than a supplier to compute infrastructure. Krystal Biotech holds no seat in Rubin or Halo and has not appeared in any of our editions to date. It carries a Closelook score, but with only one module scored so far, the score is still being built.

What does this page show?

A live price chart with SMA overlays and drawing tools for KRYS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe